Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026

Emi-Le recently received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for the proposed treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation Oral presentation shows Emi-Le was well tolerated...